PremiumCompany AnnouncementsAstraZeneca Advances Dual ATTR-CM Therapy With New Phase IIb Trial6h agoAZN
PremiumCompany AnnouncementsAstraZeneca’s New Obesity Drug AZD1043 Enters Early Human Testing: What Investors Should Watch6h agoAZN
PremiumCompany AnnouncementsAstraZeneca Advances AZD5004 With Completed Phase 1 Formulation Study6h agoAZN
PremiumCompany AnnouncementsRoyal Bank of Canada Launches New Bid to Repurchase Up to 45 Million Shares7h ago6KRY